Headshot of Clare Stuart smiling

Clare Stuart, Mito Foundation’s Advocacy and Engagement Manager, recently returned from the Health Technology Assessment International (HTAi) conference. Here, Clare shares what she learned—and why it matters for the Australian mito community.

Attending the HTAi conference was a valuable opportunity to deepen my understanding of something called Health Technology Assessment—and to think about how the Mito Foundation and the Australian mitochondrial disease (mito) community can play a bigger role in it in the future.

This is especially timely. After years of research and hope, new treatments for mito are starting to emerge from clinical trials. But before these treatments can reach Australian patients, they’ll need to go through a formal review process to decide if they should be funded and made available. That’s where Health Technology Assessment comes in.

What is Health Technology Assessment?

Despite the name, Health Technology Assessment (HTA) isn’t just about high-tech gadgets. In health care, “technologies” can mean medicines, vaccines, diagnostic tests, medical devices, and even health services like counselling or home care.

HTA is the process used by governments and health systems to decide whether new health technologies should be publicly funded—in other words, whether they’ll be accessible through Medicare or listed on the Pharmaceutical Benefits Scheme (PBS) in Australia.

These decisions look at many factors, including:

  • How well the treatment works
  • Whether it’s safe
  • What it costs
  • And crucially, how it affects people’s lives.

Why the mito community needs a seat at the table

Experts from many areas came together at the conference. These included researchers, health economists, government decision-makers, companies that develop treatments—and patient advocates like me.

This year, I was proud to attend thanks to a scholarship from the Patient Voice Initiative. It gave me the chance to connect with other rare disease advocates, including people working with communities affected by muscular dystrophy and Angelman syndrome.

One big takeaway? The patient voice is becoming more important than ever in HTA. Decisions about new treatments aren’t only about clinical trial results. They also depend on understanding what matters most to the people who live with the condition.

Mito Foundation is already contributing

Mito Foundation has already had a say in important HTA decisions. We’ve represented the community in decisions about:

  • Medicare funding for genomic testing for mito
  • Reproductive genetic carrier screening
    Access to genetic counselling
  • Continuous glucose monitoring for people with diabetes symptoms related to mito.

But we know more work is ahead.

Pictured 2025 patient voice partners: Clare Stuart, Cara Philpott and Meagan Cross with Patient Voice Initiative CEO Ann Single and Kris at the Health Technology Assessment international conference 2025.

Pictured 2025 patient voice partners: Clare Stuart, Cara Philpott and Meagan Cross with Patient Voice Initiative CEO Ann Single and Kris at the HTAi 2025 conference.

Getting ready for future treatments

As new mito treatments come closer to assessment, we’re focused on making sure decision-makers understand:

  • What life is really like with mito
  • Which symptoms are most disruptive
  • What improvements would make the biggest difference
  • What living with a treatment looks like in the real world.

These stories and insights don’t replace scientific evidence—but they add vital context. One conference discussion was the value of combining data from clinical trials with the lived experience shared by patients and families. That’s exactly what we’ve started to do through our Mito Stories Project.

Putting equity at the centre

Another major theme at the conference was equity—how to include people who are often left out of these decision-making processes. In Australia, that means making sure voices are heard from First Nations people, culturally and linguistically diverse communities, and those living with disability. There’s still a long way to go, but I was encouraged to see examples from around the world showing how we can do better.

How you can help

We expect that new medicines for mito could go through HTA in Australia within the next year or 2. To be ready, we need the support and input of our whole community.
If you or someone you love is affected by mito, please consider:

Your voice can help shape the future of treatment access in Australia—and bring hope to families affected by mitochondrial disease.